PRNewsWire
17 Aug 2026, 07:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Capricor Therapeutics is facing a securities fraud class action lawsuit alleging it made false and misleading statements regarding the clinical data for Deramiocel. — Lawsuits alleging fraud and misleading data typically damage investor confidence and create significant legal and financial liabilities for biotech firms.
-0.60The company allegedly altered its statistical analysis plan for Deramiocel without FDA agreement prior to resubmitting its Biologics License Application (BLA). — Unauthorized changes to analysis plans increase the risk of FDA rejection, which is a binary and high-impact event for a company's valuation.
-0.50The complaint claims Capricor faced a significant risk that the FDA would not approve the BLA due to insufficient evidence of effectiveness. — Direct claims of lacking efficacy for a primary product candidate are fundamentally bearish for the stock's long-term outlook.
-0.40Continue reading
6 related stories
Search tags
Which stocks this story touches
The company is mentioned as the subject of a securities fraud class action lawsuit.
The company is facing a securities fraud class action lawsuit alleging false and misleading statements regarding clinical data and FDA approval risks.
The company is mentioned as the subject of a securities fraud class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
